Background Long‐acting injectable cabotegravir (CAB‐LA) represents a new additional
option for HIV prevention in people at substantial risk of HIV infection that may fill the gaps in …

HIV/AIDS and maternal mortality are the two leading causes of death among women of
reproductive age in sub-Saharan Africa. A growing body of research investigates …

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may
be offered as an additional HIV prevention option for people at substantial risk of HIV …

Background Long-acting injectable cabotegravir, a drug taken every 2 months, has been
shown to be more effective at preventing HIV infection than daily oral tenofovir disoproxil …

Abstract Background Compared to women, South African men are less likely to know their
HIV status (78% vs. 89%), have suppressed viral loads (82% vs. 90%), or access HIV …

PrEP user profiles, dynamics of PrEP use and follow‐up: a co... : African Journal of Reproduction
and Gynaecological Endoscopy PrEP user profiles, dynamics of PrEP use and follow‐up: a …

Purpose This study describes a cohort of men seeking oral pre-exposure prophylaxis (PrEP)
services and explores their patterns of PrEP use within an implementation project seeking to …

Background Although effective, some oral pre-exposure prophylaxis (PrEP) users face
barriers to adherence using daily pills, which could be reduced by long-acting formulations …

Abstract Introduction South Africa has one of the highest rates of internal migration on the
continent, largely comprised of men seeking labour in urban centres. South African men who …

Abstract Background and Objective Although HIV prevention science has advanced over the
last four decades, evidence suggests that prevention technologies do not always reach their …